Abbott completed its $23 billion acquisition of Exact Sciences after securing regulatory clearances, bringing the Cologuard multi‑cancer and colorectal screening products, Oncotype DX, and other molecular diagnostics into Abbott’s diagnostics portfolio. Abbott expects the deal to add roughly $3 billion in incremental 2026 sales and to expand its footprint in cancer screening and molecular testing. Company leadership framed the transaction as a strategy to strengthen Abbott’s diagnostics leadership and accelerate growth in cancer screening markets. The acquisition raises integration, reimbursement and channel questions for the combined businesses, but it markedly shifts Abbott’s exposure toward high‑value molecular diagnostics.